Ibrexafungerp citrate

USDailyMed:Ibrexafungerp Contraindicated J02AX07(WHO) US:℞-only (1R,5S,6R,7R,10R,11R,14R,15S,20R,21R)-21-[(2R)-2-amino-2,3,3-trimethylbutoxy]-5,7,10,15-tetramethyl-7-[(2R)-3-methylbutan-2-yl]-20-(5-pyridin-4-yl-1,2,4-triazol-1-yl)-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid 1207753-03-4as citrate:1965291-08-0 46871657as citrate:137552087 DB12471as citrate:DBSALT003185 A92JFM5XNUas citrate:M4NU2SDX3E D11544as citrate:D11545 ChEMBL4297513as citrate:ChEMBL4298168 DTXSID901336871 Interactive image CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@@H](n​​​‍​​‍​​​​‍​​‍‍4ncnc4-c4ccncc4)[C@@H]5OC[C@](C)(N)C(C)(C)C)C3=CC[C@@]2(C)[C@@H]1C(=O)O InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1Key:BODYFEUFKHPRCK-ZCZMVWJSSA-N Ibrexafungerp, sold under the brand nameBrexafemme, is anantifungal medicationused to treatvulvovaginal candidiasis(VVC) (vaginal yeast infection).It is takenorally(by mouth).It is also currently undergoing clinical trials for other indications via anintravenous(IV) formulation. An estimated 75% of women will have at least one episode of VVC and 40 to 45% will have two or more episodes in their lifetime. Ibrexafungerp acts viainhibitionofglucan synthase, which prevents formation of the fungalcell wall. Ibrexafungerp was approved for medical use in the United States in June 2021.It is the first non-azoleoral antifungal drug to be approved by the U.S.Food and Drug Administration(FDA) for the treatment of vaginal yeast infections.The FDA considers it to be afirst-in-class medication.